Emergency use of Covishield vaccine approved by Nepal
On Friday, Nepal government approved the emergency use of Covishield vaccine manufactured by the Serum Institute of India. This decision was taken by the Department of Drug Administration.
“It is to notify to all concerned that the conditional permission has been granted for the emergency use of Covishield vaccine against Covid-19 in Nepal as per deportmental decision dated January 15, 2021,” the DDA said in a notice.
The country has reported 2,66,816 cases since the outbreak of the disease. On the day of the sixth meeting of the India-Nepal Joint Commission when External Affairs Minister S Jaishankar with Nepal Foreign Minister Pradeep Kumar Gyawali in Delhi, Nepal congratulated India on the success of the Covishield vaccine and requested for early provisions of vaccines to Nepal. Covishield has already shown the efficacy of 90 per cent and 62 per cent in two different dosing regimes. The AstraZeneca-Oxford COVID-19 vaccine should not be administered to those who have a pre-existing severe allergic reaction during the first dose or have an identified allergy to any of the vaccine’s ingredients.
India plans to offer 20 million doses to neighbouring countries. The first batch of the vials will be shipped over the next few weeks. The government will then offer the vaccines to Latin America, Africa and the former Soviet Republics.
This is the first time that any Covid-19 vaccine has been approved for use in Nepal. Other manufacturing countries like China and Russia were also interested in providing vaccines to Nepal but due to climatic conditions, pricing, logistic facility and ease of import, Nepal preferred the Indian Covid vaccine.
“It is too early to give a specific response on the supplies to other countries as we are still assessing production schedules and delivery,” India’s foreign ministry spokesman Anurag Srivastava said.